Space Peptides Shine CPS 2024: Collaborative Blueprint for Peptide Drug Fusion Innovation

In the summer of 2024, the Hong Kong Special Administrative Region welcomed the top-level feast of the global peptide research community – 18th Chinese International Peptide Symposium (CPS 2024). CPS 2024 bought peptide researchers together around the world and promoted international communication, collaboration, and innovative applications of peptides.
Under the theme of “Integrated Development and Flourishing Peptide Potential”, the conference delved into the latest developments in cutting-edge fields such as peptides and chemistry, biology and drug discovery, and materials science. As a shining star in the field of peptide drugs and a “platinum sponsor” of this conference, Space Peptides, represented by CEO Dr.Runze HE, was invited to celebrate with colleagues around the world.
Professor Jean-Louis Reymond, Chief Scientist of Space Peptides, Founder and Major Contributor of Chemical Space New Drug Discovery Platform, and globally authoritative scientist in Peptide Drugs, attended the event and delivered a wonderful speech. Unveiling the extraordinary discovery of new peptide compounds on the Chemical Space platform; taking the breakthrough progress of antimicrobial peptide molecules AMPs with new structures and mechanisms as an example; demonstrating the company’s technological strength and drawing a grand blueprint for the future research and development of peptide drugs.
Dr.Javor Sacha, Chief Technology Officer (CTO) of Space Peptides, vividly illustrated the powerful capabilities of the Chemical Space new drug discovery platform with his unique insights into AI and big data technology. He talked about how to accelerate the process of new drug development and screening through intelligent strategies, which has sparked widespread resonance and discussion among scholars on the spot.
At this academic conference, Space Peptides showcased its profound technological accumulation in the field of new drug discovery, demonstrating the company’s leading position in peptide science research and industrialization. Space Peptides has an unwavering pursuit of scientific exploration. We deeply understand that in the vast expanse of peptide science, only by constantly moving forward can we explore the unknown and create the future. We will continue to adhere to the concept of “Innovation-Led, Technology-Driven”, continuously invest in technological innovations, rely on strong technical strength and advanced technology, and work together with colleagues around the world to promote the prosperous development of peptide science.

Space Peptides Shine in CPHI China 2024: Showcasing AI+New Drug Screening Strength

From June 19th to 21st, Space Peptides Pharmaceutical Co., Ltd.(referred to as “Space Peptides”) participated in the 22nd CPHI China 2024, attracting the attention of many industries with its unique AI new drug discovery technology and one-stop service achievements from peptide innovation drug research and development to industrial production. Dr.Runze HE, founder and CEO of Space Peptides, led the team to have in-depth communication and exchanges with partners from all over the world at booth (E2A10).

As the most influential pharmaceutical raw material exhibition in Asia, CPHI China 2024 brings together the world’s top pharmaceutical companies and professionals. On this international stage, Space Peptides demonstrated the strength and style of Chinese pharmaceutical companies to the world with its cutting-edge technology and outstanding innovation.

At this exhibition, Space Peptides introduced VR technology, combined with large LED screens, to provide customers with an immersive technological experience. Through VR glasses, delve into the Chemical Space peptide drug molecular database of Space Peptides and intuitively experience the powerful application of AI technology in drug screening. This molecular library has strong logicality, which can help scientists quickly and accurately to find peptide molecules with better drug properties. Through thinking ahead half-life, toxicity and other drug development parameters, it reduces the risk of new drug research and development, greatly reducing research and development costs and cycles.

In addition, Space Peptides highlighted the latest research and development achievements in the fields of AI and new drug screening and peptide innovation drugs, as well as the innovative capabilities and strong strength of its subsidiaries in chemical CRO, pre-clinical research, and large-scale production. Through communication and presentation at the booth, we have successfully attracted the attention of numerous potential partners and reached multiple strategic cooperation intentions. These collaborations will provide more resources and opportunities for the future development of Space Peptides and further driving the company’s breakthroughs and growth in the peptide field.

Space Peptides(Taizhou) completes a strategic financing of millions of RMB, accelerating the construction of peptide drug CRO/CDMO intelligent plant

Recently， Space Peptides (Taizhou) Pharmaceutical Co., Ltd. (referred as ” Space Peptides (Taizhou)”) announced the completion of a strategic financing of millions of RMB. This round of financing is jointly invested by leading domestic pharmaceutical listed companies Shenyang Xingqi Pharmaceutical Co., Ltd., Yichang Humanwell Pharmaceutical Co., Ltd., Industry side: Xiamen Furier Pharmaceutical Co., Ltd., and emerging venture capital fund Purple Knight Capital, which focuses on the peptide field. This investment is also the first time that Shenyang Xingqi Pharmaceutical Co., Ltd. and Yichang Humanwell Pharmaceutical have laid out in the peptide field.

Space Pharmaceuticals opens a new AI research center in Bern, Switzerland, to revolutionize drug development

We are thrilled to announce the opening of our state-of-the-art AI Research Center in Bern, Switzerland. This cutting-edge facility is dedicated to advancing the field of drug development through virtual design and compound screening. By leveraging the power of artificial intelligence, our expert team aims to accelerate the discovery of new, life-saving medications.

Our innovative approach integrates AI algorithms with advanced scientific research to identify promising drug candidates more efficiently than traditional methods. This not only shortens the development timeline but also reduces costs and enhances the precision of drug targeting.